The monomer state of beta-amyloid: where the Alzheimer's disease protein meets physiology.

M. L. Giuffrida, F. Caraci, P. De Bona, G. Pappalardo, F. Nicoletti, E. Rizzarelli, A. Copani

Research output: Contribution to journalArticle

Abstract

One hundred years of study have identified beta-Amyloid (A beta) as the most interesting feature of Alzheimer's disease (AD). Since the discovery of A beta as the principal component of amyloid plaques, the central challenge in AD research has been the understanding of A beta involvement in the neurodegenerative process of the disease. The ability of A beta to undergo conformational changes and subsequent aggregation has always been a limiting factor in finding out the activities of the peptide. Extensive research has been carried out to study the molecular mechanisms of amyloid self-assembly. The finding that soluble Abeta concentrations in the brain are correlated with the severity of AD, whereas fibrillar density is not /40,42/, has pointed attention toward the oligomeric forms of Abeta, which are generally considered the most toxic and, therefore, the most important species to be addressed. Despite great efforts in basic AD research, none of the currently available treatments is able to treat the devastating effects of the disease, leading to the consideration that there is more to reason than just A beta production and aggregation. Here we summarize the emerging evidence for the physiological functions of A beta, including our recent demonstration that A beta monomers are endowed with neuroprotective activity, and propose that A beta aggregation might contribute to AD pathology through a "loss-of-function" process. Finally, we discuss the current therapeutics targeting the cerebral load of A beta and possible new ones aimed at preserving the biological functions of A beta.

Original languageEnglish
Pages (from-to)83-93
Number of pages11
JournalReviews in the Neurosciences
Volume21
Issue number2
Publication statusPublished - 2010

Fingerprint

Amyloid
Alzheimer Disease
Proteins
Research
Aptitude
Poisons
Amyloid Plaques
Neurodegenerative Diseases
Pathology
Peptides
Brain
Therapeutics

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Giuffrida, M. L., Caraci, F., De Bona, P., Pappalardo, G., Nicoletti, F., Rizzarelli, E., & Copani, A. (2010). The monomer state of beta-amyloid: where the Alzheimer's disease protein meets physiology. Reviews in the Neurosciences, 21(2), 83-93.

The monomer state of beta-amyloid : where the Alzheimer's disease protein meets physiology. / Giuffrida, M. L.; Caraci, F.; De Bona, P.; Pappalardo, G.; Nicoletti, F.; Rizzarelli, E.; Copani, A.

In: Reviews in the Neurosciences, Vol. 21, No. 2, 2010, p. 83-93.

Research output: Contribution to journalArticle

Giuffrida, ML, Caraci, F, De Bona, P, Pappalardo, G, Nicoletti, F, Rizzarelli, E & Copani, A 2010, 'The monomer state of beta-amyloid: where the Alzheimer's disease protein meets physiology.', Reviews in the Neurosciences, vol. 21, no. 2, pp. 83-93.
Giuffrida, M. L. ; Caraci, F. ; De Bona, P. ; Pappalardo, G. ; Nicoletti, F. ; Rizzarelli, E. ; Copani, A. / The monomer state of beta-amyloid : where the Alzheimer's disease protein meets physiology. In: Reviews in the Neurosciences. 2010 ; Vol. 21, No. 2. pp. 83-93.
@article{ca75eacb55e84704ab9149d6a3edb49d,
title = "The monomer state of beta-amyloid: where the Alzheimer's disease protein meets physiology.",
abstract = "One hundred years of study have identified beta-Amyloid (A beta) as the most interesting feature of Alzheimer's disease (AD). Since the discovery of A beta as the principal component of amyloid plaques, the central challenge in AD research has been the understanding of A beta involvement in the neurodegenerative process of the disease. The ability of A beta to undergo conformational changes and subsequent aggregation has always been a limiting factor in finding out the activities of the peptide. Extensive research has been carried out to study the molecular mechanisms of amyloid self-assembly. The finding that soluble Abeta concentrations in the brain are correlated with the severity of AD, whereas fibrillar density is not /40,42/, has pointed attention toward the oligomeric forms of Abeta, which are generally considered the most toxic and, therefore, the most important species to be addressed. Despite great efforts in basic AD research, none of the currently available treatments is able to treat the devastating effects of the disease, leading to the consideration that there is more to reason than just A beta production and aggregation. Here we summarize the emerging evidence for the physiological functions of A beta, including our recent demonstration that A beta monomers are endowed with neuroprotective activity, and propose that A beta aggregation might contribute to AD pathology through a {"}loss-of-function{"} process. Finally, we discuss the current therapeutics targeting the cerebral load of A beta and possible new ones aimed at preserving the biological functions of A beta.",
author = "Giuffrida, {M. L.} and F. Caraci and {De Bona}, P. and G. Pappalardo and F. Nicoletti and E. Rizzarelli and A. Copani",
year = "2010",
language = "English",
volume = "21",
pages = "83--93",
journal = "Reviews in the Neurosciences",
issn = "0334-1763",
publisher = "Walter de Gruyter GmbH & Co. KG",
number = "2",

}

TY - JOUR

T1 - The monomer state of beta-amyloid

T2 - where the Alzheimer's disease protein meets physiology.

AU - Giuffrida, M. L.

AU - Caraci, F.

AU - De Bona, P.

AU - Pappalardo, G.

AU - Nicoletti, F.

AU - Rizzarelli, E.

AU - Copani, A.

PY - 2010

Y1 - 2010

N2 - One hundred years of study have identified beta-Amyloid (A beta) as the most interesting feature of Alzheimer's disease (AD). Since the discovery of A beta as the principal component of amyloid plaques, the central challenge in AD research has been the understanding of A beta involvement in the neurodegenerative process of the disease. The ability of A beta to undergo conformational changes and subsequent aggregation has always been a limiting factor in finding out the activities of the peptide. Extensive research has been carried out to study the molecular mechanisms of amyloid self-assembly. The finding that soluble Abeta concentrations in the brain are correlated with the severity of AD, whereas fibrillar density is not /40,42/, has pointed attention toward the oligomeric forms of Abeta, which are generally considered the most toxic and, therefore, the most important species to be addressed. Despite great efforts in basic AD research, none of the currently available treatments is able to treat the devastating effects of the disease, leading to the consideration that there is more to reason than just A beta production and aggregation. Here we summarize the emerging evidence for the physiological functions of A beta, including our recent demonstration that A beta monomers are endowed with neuroprotective activity, and propose that A beta aggregation might contribute to AD pathology through a "loss-of-function" process. Finally, we discuss the current therapeutics targeting the cerebral load of A beta and possible new ones aimed at preserving the biological functions of A beta.

AB - One hundred years of study have identified beta-Amyloid (A beta) as the most interesting feature of Alzheimer's disease (AD). Since the discovery of A beta as the principal component of amyloid plaques, the central challenge in AD research has been the understanding of A beta involvement in the neurodegenerative process of the disease. The ability of A beta to undergo conformational changes and subsequent aggregation has always been a limiting factor in finding out the activities of the peptide. Extensive research has been carried out to study the molecular mechanisms of amyloid self-assembly. The finding that soluble Abeta concentrations in the brain are correlated with the severity of AD, whereas fibrillar density is not /40,42/, has pointed attention toward the oligomeric forms of Abeta, which are generally considered the most toxic and, therefore, the most important species to be addressed. Despite great efforts in basic AD research, none of the currently available treatments is able to treat the devastating effects of the disease, leading to the consideration that there is more to reason than just A beta production and aggregation. Here we summarize the emerging evidence for the physiological functions of A beta, including our recent demonstration that A beta monomers are endowed with neuroprotective activity, and propose that A beta aggregation might contribute to AD pathology through a "loss-of-function" process. Finally, we discuss the current therapeutics targeting the cerebral load of A beta and possible new ones aimed at preserving the biological functions of A beta.

UR - http://www.scopus.com/inward/record.url?scp=77955079634&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955079634&partnerID=8YFLogxK

M3 - Article

C2 - 20614800

AN - SCOPUS:77955079634

VL - 21

SP - 83

EP - 93

JO - Reviews in the Neurosciences

JF - Reviews in the Neurosciences

SN - 0334-1763

IS - 2

ER -